Taltz improves signs, symptoms of ankylosing spondylitis

Ixekizumab demonstrated a statistically significant improvement in the signs and symptoms of ankylosing spondylitis compared with placebo, according to an Eli Lilly press release.
The findings are the result of the phase 3 COAST-W study, a multicenter, randomized, double-blind 16-week trial that evaluated the safety and efficacy of ixekizumab (Taltz, Eli Lilly) for the treatment of AS, the company said. The study included patients who have an intolerance of, or had an inadequate response to, TNF inhibitors.
“These positive results, in combination with previous results from the phase 3

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button